Dynavax price target raised to $33 from $29 at Citizens JMP

Citizens JMP raised the firm’s price target on Dynavax (DVAX) to $33 from $29 and keeps an Outperform rating on the shares. Dynavax reported fiscal 2024 results in line with January’s preannouncement, and management remains optimistic on the potential for bringing in value-add, late-stage assets in the infectious disease space as the best way to maximize the value of its hepatitis B vaccine, HEPLISAV-B, the analyst tells investors in a research note. Management also continues to seek out assets in the infectious disease space, and believes there are viable assets, the firm notes.